Enacts the "New York affordable drug manufacturing act" to direct the commissioner of health to enter into partnerships to increase competition, lower prices, and address shortages in the market for generic prescription drugs, to reduce the cost of prescription drugs for public and private purchasers, taxpayers, and consumers, and to increase patient access to affordable drugs.
Requires that services at addiction treatment centers operated by the office of addiction services and supports shall not be refused at such centers if a person is unable to pay.
Creates a wholesale prescription drug importation program which complies with federal standards and regulations for the purpose of generating substantial savings for consumers.
Relates to preserving access to affordable drugs; provides that an agreement resolving or settling, on a final or interim basis, a patent infringement claim, in connection with the sale of a pharmaceutical product, shall be presumed to have anticompetitive effects if a nonreference drug filer receives anything of value from another company asserting patent infringement and if the nonreference drug filer agrees to limit or forego research, development, manufacturing, marketing, or sales of the nonreference drug filer's product for any period of time.
Establishes a quality incentive program for managed care providers that is distributed based on managed care providers' performance in meeting quality objectives.
This bill (S 8756) modifies the implementation timeline for a law allowing close friends to arrange body donations for medical purposes after a person's death. It changes the effective date so that the health commissioner can immediately begin implementing the law - rather than waiting 180 days - upon the bill's passage. This adjustment primarily affects individuals who wish to donate a deceased person's body for medical education or research, ensuring faster administrative readiness. The bill is procedural in nature, focusing solely on implementation timing, not the eligibility for body donations.
This bill requires insurers and health care plans to follow specific rules when using virtual credit cards or fee-based digital payment methods to reimburse healthcare providers. Insurers must first notify providers of any potential fees, offer a fee-free payment alternative, and get the provider's written consent within 30 days to use the fee-based method. If a provider doesn't respond in time, insurers must default to the fee-free option. The law applies directly to insurers and healthcare providers who contract with them, ensuring transparency and preventing unexpected charges for providers.
This bill changes the language in New York's Public Health Law by replacing the term "addict" with "person with substance use disorder" in sections governing medical treatment. It specifically affects healthcare practitioners who prescribe controlled substances for maintenance or detoxification treatment, ensuring they reference patients as "person with substance use disorder" instead of "addict" in legal documents. The key mechanism is a simple terminology update within existing prescribing provisions, aiming to use more clinical and less stigmatizing language. This change aligns with broader efforts to reduce stigma in healthcare communication.
This bill establishes legal confidentiality for conversations between police officers and peer support specialists during official counseling sessions. It directly affects law enforcement officers seeking mental health support and the peer support specialists who provide it. Key provisions prohibit disclosing session details unless there's a specific threat of suicide, self-harm, violence, or child abuse - allowing limited disclosure only to prevent harm. Officers must receive written notice before sessions explaining these confidentiality rules and exceptions. The law ensures peer support communications remain private except in clearly defined safety emergencies.
This bill (A 9491) requires courts and mental health institutions to coordinate discharge planning for defendants in criminal cases terminated due to mental disease or defect. It mandates that courts order referrals to community services (when clinically appropriate and with consent) and dismiss charges upon termination, while institutions must track referrals and submit de-identified annual reports to state officials. The mental hygiene law office must publish annual public data on defendant outcomes, including admission rates, discharge planning, and referral patterns. The bill directly affects defendants in such cases, courts, mental health facilities, and state agencies, without altering eligibility for services or requiring referrals where consent is absent.